These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 35446267)
1. Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma. Mulder EEAP; Damman J; Verver D; van der Veldt AAM; Tas S; Khemai-Mehraban T; Heezen KC; Wouters RA; Verhoef C; Verjans GMGM; Langerak AW; Grünhagen DJ; Mooyaart AL Melanoma Res; 2022 Aug; 32(4):249-259. PubMed ID: 35446267 [TBL] [Abstract][Full Text] [Related]
2. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model. Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342 [TBL] [Abstract][Full Text] [Related]
3. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293 [TBL] [Abstract][Full Text] [Related]
4. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610 [TBL] [Abstract][Full Text] [Related]
5. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Gangi A; Zager JS Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216 [TBL] [Abstract][Full Text] [Related]
6. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650 [TBL] [Abstract][Full Text] [Related]
8. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Andtbacka RH; Ross M; Puzanov I; Milhem M; Collichio F; Delman KA; Amatruda T; Zager JS; Cranmer L; Hsueh E; Chen L; Shilkrut M; Kaufman HL Ann Surg Oncol; 2016 Dec; 23(13):4169-4177. PubMed ID: 27342831 [TBL] [Abstract][Full Text] [Related]
9. False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). Mulder EEAP; Stahlie EHA; Verver D; Lemstra C; Been LB; Mooyaart AL; Brabander T; Vegt E; Verburg FA; van der Veldt AAM; Verhoef C; van Akkooi ACJ; Grünhagen DJ J Surg Oncol; 2021 Dec; 124(7):1161-1165. PubMed ID: 34235758 [TBL] [Abstract][Full Text] [Related]
10. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Yamazaki N; Isei T; Kiyohara Y; Koga H; Kojima T; Takenouchi T; Yokota K; Namikawa K; Yi M; Keegan A; Fukushima S Cancer Sci; 2022 Aug; 113(8):2798-2806. PubMed ID: 35656636 [TBL] [Abstract][Full Text] [Related]
11. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey. Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. Burke EE; Zager JS Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682 [TBL] [Abstract][Full Text] [Related]
13. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries. van Akkooi ACJ; Haferkamp S; Papa S; Franke V; Pinter A; Weishaupt C; Huber MA; Loquai C; Richtig E; Gokani P; Öhrling K; Louie KS; Mohr P Adv Ther; 2021 Feb; 38(2):1245-1262. PubMed ID: 33368016 [TBL] [Abstract][Full Text] [Related]
14. Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis. Stahlie EHA; Mulder EEAP; Reijers S; Balduzzi S; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; Grunhagen DJ; van Akkooi ACJ Crit Rev Oncol Hematol; 2022 Jul; 175():103705. PubMed ID: 35569723 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial. Rohaan MW; Stahlie EHA; Franke V; Zijlker LP; Wilgenhof S; van der Noort V; van Akkooi ACJ; Haanen JBAG BMC Cancer; 2022 Aug; 22(1):851. PubMed ID: 35927710 [TBL] [Abstract][Full Text] [Related]
16. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555 [TBL] [Abstract][Full Text] [Related]
17. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039 [TBL] [Abstract][Full Text] [Related]
18. Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report. Ressler J; Silmbrod R; Stepan A; Tuchmann F; Cicha A; Uyanik-Ünal K; Hoeller C Br J Dermatol; 2019 Jul; 181(1):186-189. PubMed ID: 30776080 [TBL] [Abstract][Full Text] [Related]
19. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145 [TBL] [Abstract][Full Text] [Related]
20. Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective. Franke V; Stahlie EHA; van der Hiel B; van de Wiel BA; Wouters MWJM; van Houdt WJ; van Akkooi ACJ J Immunother; 2022 Jul-Aug 01; 45(6):263-266. PubMed ID: 35580326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]